Cours | Graphes | News | Analyses et conseils | Société | Historiques | Vie du titre | Secteur | Forum |
Boiron and Lehning laboratories wish to announce that they have asked the Conseil d'Etat (France's highest administrative court) to quash the following orders:
These appeals focus on both the irregularities which have tainted the homoeopathy assessment procedure conducted by the French Health Authority transparency commission, and the ill-founded nature of these decrees.
An application for a priority preliminary ruling on the issue of constitutionality (QPC) will also be presented in order to challenge the law, which delegated the decision concerning coverage of homoeopathic medicines to a single minister.
Filing these appeals triggers the start of a procedure which could last between 12 and 18 months. The laboratories will not comment on changes to the dossier before the Conseil d'Etat announces its decision.
Filing these appeals is also a statement of how confident these laboratories are as to the efficacy of homoeopathy and its validity and relevance to public health, as well as their desire to ensure access for all to this type of therapy.
Press contact: DGM – Thomas de Climens – thomasdeclimens@dgm-conseil.fr - 0614501584
Vous avez aimé cet article ? Partagez-le avec vos amis avec les boutons ci-dessous.
25/04/24
Mise à disposition du Rapport Financier Annuel 2023
02/04/24
Boiron annonce des résultats en recul en 2023 après la baisse des ventes de tests Covid
02/04/24
CHIFFRE D'AFFAIRES ET RÉSULTATS 2023
21/03/24
Éligibilité des titres BOIRON au PEA-PME
Pour poster un commentaire, merci de vous identifier.